Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men

Journal of Urology

Volumn 159, Issue 2, 1998, Pages 441-443

  Cooper, Christopher S ^a   Perry, Paul J ^a   Sparks, Amy E T ^a   MacIndoe, John H ^a   Yates, William R ^a   Williams, Richard D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Prostate; Prostate specific antigen; Semen; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0031975843     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63944-2     Document Type: Article

References (25)

1. Cooper, C. S., MacIndoe, J. H., Perry, P. J., Yates, W. R. and Williams, R. D.: The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J. Urol., 156: 438, 1996.
2. Takeuchi, S., Yoshida, K., Tosaka, A., Kobayashi, N., Uchijima, Y. and Saitoh, H.: Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer. Acta Urol. Jap., 40: 393, 1994.
3. Sohlberg, O., Brawer, M. K., Matsumoto, A. and Lange, P. H.: Androgen provocative testing (APT) after radical prostatectomy (RP). J. Urol., part 2, 143: 315A, abstract 507, 1990.
4. Sasagawa, I., Nakada, T., Kubota, Y., Sawamura, T. and Izumiya, K.: Changes in the serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone releasing hormone analogue administration in patients with metastatic prostate cancer in relation to glandular differentiation. Int. Urol. Nephrol., 27: 769, 1995.
5. Kim, E. D., Smith, N. D. and Grayhack, J. T.: Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma. J. Urol., 154: 1802, 1995.
6. Kaufman, M., Pinsky, L., Trifiro, M., Lumbrosco, R., Sabbaghian, N. and Gottlieb, B.: Kinetic evidence for a unique testosterone-receptor complex in 5α-reductase sufficient genital skin fibroblasts and the effects of 5α-reductase deficiency on its formation. J. Steroid Biochem. Mol. Biol., 45: 467, 1993.
7. Kokontis, J., Takakura, K., Hay, N. and Liao, S.: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res., 54: 1566, 1994.
8. Murtha, P., Tindall, D. J. and Young, C. Y. F.: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry, 32: 6459, 1993.
9. Riegman, P. H. J., Vliestra, R. J., van der Korput, J. A. G. M., Romijn, J. C. and Trapman, J.: Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem. Biophys. Res. Comm., 159: 95, 1989.
10. Geller, J.: Basis for hormonal management of advanced prostate cancer. Cancer, 71: 1039, 1993.
11. Siiteri, P. K. and Simberg, N. H.: Changing concepts of active androgens in blood. Clin. Endocr. Metab., 15: 247, 1986.
12. Behre, H. M. and Nieschlag, E.: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocr. Metab., 75: 1204, 1992.
13. Behre, H. M., Bohmeyer, J. and Nieschlag, E.: Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocr., 40: 341, 1994.
14. Tenover, J. S.: Effects of testosterone supplementation in the aging male. J. Clin. Endocr. Metab., 75: 1092, 1992.
15. Wallace, E. M., Pye, S. D., Wild, S. R. and Wu, F. C. W.: Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. Int. J. Androl., 16: 35, 1993.
16. Carpino, A., Sisci, D., Aquila, S., Beraldi, E., Sessa, M. T., Siciliano, L., De Luca, G. and Andò, S.: Effects of short-term high-dose testosterone propionate administration on medium molecular-weight proteins of human seminal plasma. Andrologia, 26: 241, 1994.
17. Weber, J. P., Oesterling, J. E., Peters, C. A., Partin, A. W., Chan, D. W. and Walsh, P. C.: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J. Urol., 141: 987, 1989.
18. Young, C. Y., Montgomery, B. T., Andrews, P. E., Qiu, S. D., Bilhartz, D. L. and Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748, 1991.
19. Henttu, P., Liao, S. S. and Vihko, P.: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 130: 766, 1992.
20. Gleave, M. E., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C. and Chung, L. W.: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598, 1992.
21. Horton, R., Pasupuletti, V. and Antonipillai, I.: Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology, 133: 447, 1993.
22. Griffiths, K., Eaton, C. L., Harper, M. E., Peeling, B. and Davies, P.: Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur. Urol., suppl., 20: 68, 1991.
23. Fjösne, H. E., Haug, E. and Sunde, A.: Androgen metabolism in the different lobes of the prostate gland of intact, gonadectomized or hypophysectomized rats with or without androgen substitution. Scand. J. Clin. Lab. Invest., 54: 83, 1994.
24. Shao, T. C., Kong, A., Marafelia, P. and Cunningham, G. R.: Effects of finasteride on the rat ventral prostate. J. Androl., 14: 79, 1993.
25. Shao, T. C., Kong, A. and Cunningham, G. R.: Effects of 4-MAPC, a 5α-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate. Prostate, 24: 212, 1994.